- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: A-968660 | ABT 348 | ABT-348 | ABT348
Compound class: Synthetic organic
Comment: Ilorasertib (ABT-348) is an ATP-competitive, multi-target kinase inhibitor with activity against the Aurora kinases, the VEGFR, PDGFR and Src family kinases .
ABT-348's potent inhibition of Aurora B induces polyploidy, a hallmark of the essential role of Aurora B in cytokinesis.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.
|Summary of Clinical Use
|Phase 1 studies of ABT-348 have been completed in patients with ALL, AML, B cell CLL, and advanced solid malignaicies. A Phase 2 trial in CDKN2A deficient solid tumours (NCT02478320) is underway.
|Clinical Trial ID
|Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors
|Phase 2 Interventional
|M.D. Anderson Cancer Center